



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/090,320
	Filing Date	March 1, 2002
	First Named Inventor	Cao, et al.
	Group Art Unit	TBD
	Examiner Name	TBD
Total Number of Pages in This Submission	Attorney Docket Number	3446

RECEIVED

JUL 15 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Additional Enclosure(s) (please identify below): <div>Three References Form PTO 1449 Return Receipt Postcard</div>
Remarks		The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Deposit Account No. 01-0431.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Leticia Block, Reg. No.: 50,167
Signature	Leticia R. Block
Date	July 3, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date July 3, 2002			
Typed or printed name	Sylvia Rogers		
Signature	Sylvia Rogers	Date	7/3/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT  
Attorney Docket No. 3446

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Cao et al.

Serial No: 10/090,320

Filing Date: March 1, 2002

**Title: Methods for Gene Expression  
Analysis**

Examiner: TBD

Group Art Unit: TBD

**RECEIVED**

JUL 15 2002

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 CFR § 1.56, § 1.97 and § 1.98, the documents listed on the accompanying U.S. Patent & Trademark Office's Modified Form-1449 are called to the attention of the Examiner for the above patent application.

Citation of these documents shall not be construed as (1) an admission that the documents are necessarily prior art with respect to the instant invention; (2) a representation that a search has been made, other than as described above; or (3) an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b). Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 01-0431. Please deduct any additional fees from, or credit any overpayment to the above-noted Deposit Account.

Respectfully submitted,

*Leticia R. Block*

Leticia Block

Reg. No.: 50,167

Date: July 3, 2002

PTO-1449 (Modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 3446	SERIAL NUMBER: 10/090,320
	APPLICANT: Cao, et al.	
	FILING DATE: 03/01/2002	GROUP ART UNIT: TBD

RECEIVED

JUL 15 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLA TION YES/NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Andrew P. Feinberg and Bert Vogelstein, "A Technique for Radiolabeling DNA Restriction Endonuclease Fragments to High Specific Activity, Analytical Biochemistry, 1983 July, 1;132(1), 6-13 (1983).
	Carsten Rosenow, et al., "Prokaryotic RNA Preparation Methods Useful for High Density Array Analysis: Comparison of Two Approaches", 2001 Oxford University Press, Nucleic Acids Research 2001, Vol. 29. No 22 e112, Received May 23, 2001; Revised September 21, 2001, Accepted September 29, 2001, 8 pp.
	CyScribe First-Strand cDNA Labelling Kit, Instructions, Product Code RPN 6200, 6201, 6202, Amersham Pharmacia biotech, RPN6200PL, Rev-C, 2000, 32 pp.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	